The effect of zolpidem on operant behavior and its relation to pharmacokinetics after intravenous and subcutaneous administration: Concentration-effect relations

Behavioural Pharmacology

Volumn 13, Issue 2, 2002, Pages 93-103

  Lau, Chyan E ^a   Sun, L ^a   Wang, Q ^a   Falk, J L ^a  

^a Phita International Corp   (United States)

Author keywords

Benzodiazepines; Concentration effect relations; DRL schedule; Pharmacodynamics; Pharmacokinetics; Rat; Routes of administration; Zolpidem

Indexed keywords

ZOLPIDEM;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; IC 50; INSTRUMENTAL CONDITIONING; MALE; NONHUMAN; RAT; REINFORCEMENT; RESPONSE TIME;

EID: 0036240047     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-200203000-00001     Document Type: Article

References (39)

1. A new look at the statistical model identification
2. Pharmacological profile of zolpidem at benzodiazepine receptors and electrocorticogram in rats
3. Comparison of the effects of zolpidem and triazolam on memory functions, psychomotor performances, and postural sway in healthy subjects
4. Zolpidem, a novel non-benzodiazepine hepnotic. I. Neuropharmacological and behavioral effects
5. Pharmacokinetic and metabolic profiles of zolpidem
6. Pharmacokinetics, brain, distribution and pharmaco-electrocorticographic profile of zolpidem, a new hypnotic, in the rat
7. Comparative kinetics and response to the benzodiazepine agonists trizolam and zolpidem: Evaluation of sex-dependent differences
8. Zolpidem and alpidem: Two imidazopyridines with selectivity for omega 1- and omega 3-receptor subtypes
9. Zolpidem: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential
10. Pharmacokinetic-pharmacodynamic modeling of stimulatory and sedative effects of alprazolam: Timing performance deficits
11. Alprazolam, caffeine and their interaction: Relating DRL performance to pharmacokinetics
12. Pharmacokinetics and bioavailability of midazolam after intravenous, subcutaneous, intraperitoneal and oral administration under a chronic food-limited regimen: Relating DRL performance to pharmacokinetics
13. Differential reinforcement of low rate performance, pharmacokinetics and pharmacokinetic-pharmacodynamic modeling: Independent interaction of alprazolam and caffeine
14. Independent interaction of alprazolam and caffeine under chronic dose regimens on DRL performance
15. Pharmacokinetic-pharmacodynamic modeling of the coexistence of stimulatory and sedative components for midazolam
16. Pharmacokinetic-pharmacodynamic modeling of the psychomotor stimulant effect of cocaine after intravenous administration: Timing performance deficits
17. Pharmacokinetic determinants of cocaine's differential effects on locomotor and operant behavior
18. Oral cocaine pharmacokinetics and pharmacodynamics in a cumulative-dose regimen: Pharmacokinetic-pharmacodynamic modeling of concurrent operant and spontaneous behavior within an operant context
19. Cocaine pharmacodynamics after intravenous and oral administration in rats: Relation to pharmacokinetics
20. Antagonism by CGS 8216 and Ro 15-1788, benzodiazepine antagonists, of the action of chlordiazepoxide on timing behavior in rats
21. Hypnotic activity of an imidazopyridine (zolpidem)
22. Benzodiazepines and zolpidem for chronic insomnia: A meta-analysis of treatment efficacy
23. The effects of alprazolam on corticotropin-releasing factor neurons in the rat brain: Acute time course, chronic treatment and abrupt withdrawal
24. Differences in pharmacological profiles of a new generation of benzodiazepine and non-benzodiazepine hypnotics
25. Oxidative metabolism of zolpidem by human liver cytochrome P450s
26. Sedative, memory, and performance effects of hypnotics
27. Behavioral pharmacology of zolpidem relative to benzodiaepines: A review
28. Zolpidem, triazolam, and temazepam: Behavioral and subject-rated effects in normal volunteers
29. Investigation of the development of tolerance to the actions of zolpidem and midazolam
30. A receptors
31. Differential effects of chlordiazepoxide and d-amphetamine on responding maintained by a DRL schedule of reinforcement
32. The behavioral profile of zolpidem, a novel hypnotic drug of imidazopyridune structure
33. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to D-tubocurarine
34. Differential effects of anxiolytic and non-anxiolytic benzodiazepine receptor ligands on performance of a differential reinforcement of low rate (DRL) schedule
35. Intravenous and oral clozapine pharmacokinetics, pharmacodynamics, and concentration-effect relations: Acute tolerance
36. Pharmacokinetics and metabolism of zolpidem in various animal species and in humans
37. Zolpidem metabolism in vitro: Responsible cytochromes, chemical inhibitors, and in vivo correlations
38. Determination of zolpidem in serum microsamples by high-performance liquid chromatography and its application to pharmacokinetics in rats